Click here to view the CareFirst BCBS Blue Cross Blue Shield Medical Policy Updates »…
BCBS Tennessee Medical Policy Updates – May 2021
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates »
May 2021 BCBS Tennessee Medical Policy Updates:
- AbobotulinumtoxinA (Dysport®)
- Atezolizumab (Tecentriq®)
- Azacitidine (Vidaza®)
- Burosumab-twza (Crysvita®)
- Darbepoetin Alfa for Dialysis (Aranesp®)
- Darbepoetin Alfa for Non-Dialysis (Aranesp®)
- Dostarlimab-gxly (Jemperli®)
- Epoetin Alfa Products for Dialysis (Epogen®, Procrit®, Retacrit )®
- Epoetin Alfa Products for Non-Dialysis (Epogen®, Procrit®, Retacrit )®
- Gemcitabine in Sodium Chloride Injection (Infugem®)
- Idecabtagene Vicleucel (Abecma®)
- IncobotulinumtoxinA (Xeomin®)
- Ixabepilone (Ixempra®)
- Loncastuximab Tesirine-lpyl (Zynlonta™)
- Methoxy Polyethylene Glycol-Epoetin Beta for Dialysis (Mircera®)
- Methoxy Polyethylene Glycol-Epoetin Beta for Non-Dialysis (Mircera®)
- Mitomycin Gel (Jelmyto®)
- Nivolumab (Opdivo®) (Intravenous)
- OnabotulinumtoxinA (Botox®)
- Positron Emission Tomography (PET) for Miscellaneous Applications
- RimabotulinumtoxinB (Myobloc®)
- Talimogene Laherparepvec (Imlygic®)
- Temsirolimus (Torisel®)
Added 5/25/2021;
- Ado-Trastuzumab (Kadcyla®)
- Atezolizumab (Tecentriq®)
- Avelumab (Bavencio®)
- Balloon and Self-Expanding Absorptive Ostial Dilation for Treatment of Rhinosinusitis
- Belinostat (Beleodaq®)
- Bendamustine Products (Treanda®, Belrapzo®, Bendeka®)
- Bevacizumab Products for the Treatment of Neoplastic Disease
- Brentuximab Vedotin (Adcetris®)
- Bulking Agents for the Treatment of Vesicoureteral Reflux (VUR) and Incontinence
- Casimersen (Amondys 45™)
- Cetuximab (Erbitux®)
- Daratumumab (Darzalex®)
- Donor Lymphocyte Infusion for Hematologic Malignancies Treated with an Allogeneic Hematopoietic Stem Cell Transplant
- Durvalumab (Imfinzi®)
- Eculizumab
- Electrical Stimulation and Electromagnetic Therapy for the Treatment of Wounds
- Electrical Stimulation for the Treatment of Arthritis
- Elotuzumab (Empliciti®)
- Evinacumab-dgnb (Evkeeza™)
- Fetal Surgery for Prenatally Diagnosed Malformations
- Fosdenopterin (Nulibry™)
- Genetic Testing for Cutaneous Malignant Melanoma
- Genetic Testing for Warfarin Dose
- Hematopoietic Stem Cell Transplantation for Central Nervous System Embryonal and Ependymoma Tumors
- Implantable Sinus Stents and Drug-eluting Implants for Postoperative Use Following Endoscopic Sinus Surgery and for Recurrent Sinus Disease
- In Vitro Particle Size Measurement for Screening Hypersensitivity Reactions to Foods and Chemicals
- Intracellular Micronutrient Analysis
- Intradiscal Annuloplasty for Treatment of Discogenic Back Pain
- Intraoperative Radiation Therapy (IORT)
- Ipilimumab (Yervoy®)
- Lisocabtagene Maraleucel (Breyanzi®)
- Manipulation Under Anesthesia (MUA) of the Musculoskeletal System
- Melphalan Flufenamide (Pepaxto®)
- Mepolizumab (Nucala®)
- Microwave Ablation for Oncologic Tumors
- Negative Pressure Wound Therapy in the Outpatient Setting
- Non-Contact Ultrasound Treatment for Wounds
- Noninvasive Fractional Flow Reserve Measurement
- Novel Biomarkers for the Diagnosis and Management of Prostate Cancer
- Obinutuzumab (Gazyva®)
- Orthognathic Surgery
- Ovarian Cancer Tumor Markers
- Paclitaxel (Protein-Bound Particles) (Abraxane®)
- Panitumumab (Vectibix®)
- PDF: Epoprostenol_pol.pdf
- PDF: Treprostinil_pol.pdf
- Pemetrexed (Alimta®)
- Percutaneous Vertebroplasty, Kyphoplasty and Sacroplasty
- Pertuzumab (Perjeta®)
- Photodynamic Therapy (PDT) for the Treatment of Cancer, including Barrett’s Esophagus
- Plasma Exchange
- Proton Beam Therapy
- Quantitative Sensory Testing
- Radiofrequency Tissue Volume Reduction (RFTVR) for the Treatment of Upper Airway Obstruction
- Radioimmunoscintigraphy Imaging (Monoclonal Antibody Imaging) with Indium-111 Capromab Pendetide for Prostate Cancer
- Ramucirumab (Cyramza®)
- Rituximab and Hyaluronidase Human Injection (Rituxan Hycela®)
- Rituximab Products
- Trabectedin (Yondelis®)
- Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence
- Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta™)
- Trastuzumab Products – Intravenous
- Treatments for Athletic Groin Pain
Click here to view the Blue Cross Blue Shield Tennessee Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
